Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Jun 1.

Published in final edited form as: Breast Cancer Res Treat. 2019 Feb 12;175(2):297–303. doi: 10.1007/s10549-019-05158-3

Table 4.

Effects of UGT2B17 gene deletion on changes in BMD between baseline and 24 months within each AI Arm.

		UGT2B17 1/1		UGT2B17 l/2		UGT2B17 2/2
		n	mean (SD)	n	mean (SD)	n	mean (SD)	p-value
Letrozole	Hip	55	−0.79 (2.69)	70	−0.28 (0.45)	18	−1.89 (6.46)	0.49
Letrozole	Spine	56	−0.31 (0.57)	70	−0.19 (0.45)	19	−0.43 (0.36)	0.85
Exemestane	Hip	61	0.10 (1.52)	49	−0.26 (0.33)	9	−0.17 (0.48)	0.58
Exemestane	Spine	60	−0.24 (0.56)	51	−0.11 (0.48)	9	−0.04 (0.66)	0.14